Perrigo's revenue declined 3% (0.7% from pricing and 2.4% from volume/mix) and adjusted earnings per share fell 12% in the second quarter. 2026 guidance for a 3% sales decline and $2.15 in adjusted EPS, both at the midpoint, was reaffirmed. Shares rose 23% in Aug. 5 intraday trading.
Perrigo is now more tapped into the higher-margin branded consumer health market, which should act as a tailwind to the top and bottom lines.
By expanding its business to focus more on branded products, Perrigo now faces stiffer competition from larger consumer healthcare product manufacturers.
|
Metric
|
PRGO
|
HLN
|
PG
|
|---|---|---|---|
Price/Earnings (Normalized) | 5.07 | 20.21 | 21.29 |
Price/Book Value | 0.72 | 1.97 | 6.23 |
Price/Sales | 0.44 | 2.90 | 4.02 |
Price/Cash Flow | 7.46 | 14.98 | 18.24 |
|
Metric
|
PRGO
|
HLN
|
PG
|
|---|---|---|---|
Quick Ratio | 1.05 | 0.51 | 0.41 |
Current Ratio | 2.32 | 0.69 | 0.68 |
Interest Coverage | −8.88 | 7.45 | 23.74 |
|
Metric
|
PRGO
|
HLN
|
PG
|
|---|---|---|---|
Return on Assets (Normalized) | −2.11% | 5.49% | 13.14% |
Return on Equity (Normalized) | −5.54% | 10.94% | 31.34% |
Return on Invested Capital (Normalized) | −0.64% | 8.05% | 19.01% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|x$q?rGNT | LOCK|y&^ZX | $68B | |||
| Haleon PLC ADR
HLN
| LOCK|!@%zbs | LOCK|>Bl | $42B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| LOCK|c@%%P!#% | LOCK|lCP@ | $42B | |||
| Zoetis Inc Class A
ZTS
| LOCK|^^v%k$c | LOCK|vM | $30B | |||
| Viatris Inc
VTRS
| LOCK|#!<#$$ | LOCK|g#z | $19B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|m? | LOCK|%YP | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|&T?VSRd | LOCK|<m< | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|@b>GZM | LOCK|fks | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|h<km^<k | LOCK|!<sR | $2B |
United States